1. Home
    2. Current page
    Blue Goat CyberBlue Goat Cyber(844) 939-4628Call
    FDA Hold Letter Response

    FDA Cybersecurity Hold Letter Response

    Review your hold letter, deadline, and evidence to scope the cybersecurity response.

    We review the hold letter, its deadline, and your existing evidence to define the technical response. The proposal identifies artifact updates, testing needs, manufacturer inputs, and dates. The FDA decides whether the response addresses its concerns.

    Point-by-point cybersecurity responses, scoped artifact updates, and testing evidence for manufacturer review.

    Book my free 30-min discovery call
    Request a written scope instead
    • Fixed fee after scoping
    • Defined deliverables
    • Deficiency responses covered

    275+ FDA submissions supported, zero cybersecurity rejections.

    Confirm the response deadline and review status in the actual FDA notice. Plan documentation, engineering fixes, retests, and manufacturer review against that deadline.

    Last updated October 26, 2026

    Free 30-min discovery call

    Tell us about your FDA hold letter

    Share a few details about your device and the FDA hold findings. We'll sign a mutual NDA, then return a written closure plan with effort and timeline, typically within one business day.

    • Check calendar availability
    • 30 minutes, your local time
    1. 1Pick a time
    2. →
    3. 2Confirm your email. That's it.
    Open calendar in a new tab

    Mutual NDA signed before the call. No pitch, a senior engineer will tell you straight if you don't need us.

    Request a written scope

    Send your device summary. A senior engineer will reply within one business day to discuss the work and inputs needed for a fixed-fee proposal. No booking required.

    Not the one who books the call? Send them our one-pager (PDF)

    About this engagement

    We review the hold letter, its deadline, and your existing evidence to define the technical response. The proposal identifies artifact updates, testing needs, manufacturer inputs, and dates. The FDA decides whether the response addresses its concerns.

    Point-by-point cybersecurity responses, scoped artifact updates, and testing evidence for manufacturer review.

    Included in your agreed scope

    • Hold-letter triage within one business day
    • Updated SPDF, SBOM, and threat model
    • Targeted pen test against FDA's specific concerns
    • Section 524B traceability matrix
    • Reviewer-ready response cover letter
    • Revisions included through hold resolution

    Trusted by medical device teams worldwide

    Intuitive Surgical logo
    bioMérieux logo
    Inogen logo
    Natera logo
    Velico Medical logo
    Medivis logo
    Spiro Robotics logo
    Nova Biomedical logo
    VitalConnect logo
    Lifecycle scope

    What's in your hold-letter response

    The proposal identifies included deliverables, exclusions, manufacturer inputs, and review responsibilities for this engagement.

    01

    Hold-letter triage on the discovery call

    Senior reviewer reads your letter, maps every finding to required artifacts, and returns a written closure plan with effort estimate.

    02

    FDA 2026 guidance aligned

    Every response is written against the February 2026 final premarket cybersecurity guidance and Section 524B(b)(1)-(3).

    03

    Evidence mapped for resubmission

    Updated cybersecurity evidence is organized with response and page references for your regulatory team to review and assemble. We do not promise that a hold will be lifted.

    04

    Targeted, not exhaustive

    We identify the documentation and testing needed to address the letter, including dependencies on other evidence. The proposal records scope and exclusions.

    05

    Direct reviewer-channel format

    Cover letter and redlines structured the way cybersecurity reviewers want: finding → response → evidence → page reference.

    06

    Fixed fee, hold-to-close

    One quote covers the response and any follow-up exchanges with the FDA until the cybersecurity hold is lifted.

    Illustrative security checks

    What FDA cybersecurity hold letters usually ask for

    Hold letters cluster around a handful of recurring asks. Recognizing the pattern in yours shortens the response cycle.

    Threat-model gaps and separate architecture-view gaps

    A response may require changes to the threat model and Threat Table, a separate Multi-Patient Harm security architecture view, or both. We identify each artifact separately in the proposal based on the FDA letter. Architecture views are not included in standalone threat modeling.

    SBOM work + optional VEX communication

    Component list without affected/not-affected/fixed/under-investigation status for each listed CVE is the second most common hold trigger.

    Documented patch delivery mechanism

    524B(b)(1) requires a written description of how patches reach fielded devices. Verbal process descriptions get held; controlled outputs don't.

    Pen test mapped to the threat model

    Reviewers want to see each pen test finding traced back to a threat-model entry. Standalone pen test reports get held for traceability.

    What happens after you book the call

    1. 1Scoping

      Review your letter and evidence

      Discuss architecture, available records, access, responsibilities, and target dates. Agree confidential handling before transferring device material.

    2. 2Proposal

      Agree deliverables, fee, and dates

      The proposal identifies included work, exclusions, manufacturer inputs, and delivery milestones. The 24-hour quote turnaround is separate from delivery, remediation, and review time.

    3. 3Agreed dates

      Prepare the response evidence

      Update the artifacts and testing identified by the letter review. Deliver a point-by-point response with evidence references for your regulatory team to review and submit. The FDA decides the outcome.

    "Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly what reviewers want to see."
    Scott Odland, Solutions Architect, Rhaeos

    Blue Goat Cyber vs. the alternatives

    What you actually get versus a generic regulatory consultant or a re-spin in-house while the clock burns.

    Hold-letter response track record

    Blue Goat
    Routine - written for the reviewer who sent it
    Generic regulatory consultant
    Treats hold like any other AI letter
    In-house
    First time under hold pressure

    Speed under deadline

    Blue Goat
    Dates agreed after letter and evidence review
    Generic regulatory consultant
    Hourly, drifts with scope
    In-house
    Competes with launch work

    Point-by-point response mapping

    Blue Goat
    Mirrors hold-letter exactly
    Generic regulatory consultant
    General rewrite, items missed
    In-house
    Built from scratch under pressure

    Evidence package

    Blue Goat
    Updated SPDF + SBOM/VEX + threat model + pen test
    Generic regulatory consultant
    Documentation only, no fresh testing
    In-house
    Multiple owners, integration gaps

    Pricing model

    Blue Goat
    Fixed fee, revisions included
    Generic regulatory consultant
    Hourly + change orders
    In-house
    Hidden internal cost
    CapabilityBlue Goat CyberGeneric regulatory consultantIn-house
    Hold-letter response track recordRoutine - written for the reviewer who sent itTreats hold like any other AI letterFirst time under hold pressure
    Speed under deadlineDates agreed after letter and evidence reviewHourly, drifts with scopeCompetes with launch work
    Point-by-point response mappingMirrors hold-letter exactlyGeneral rewrite, items missedBuilt from scratch under pressure
    Evidence packageUpdated SPDF + SBOM/VEX + threat model + pen testDocumentation only, no fresh testingMultiple owners, integration gaps
    Pricing modelFixed fee, revisions includedHourly + change ordersHidden internal cost

    Support matched to your scope

    If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.

    Mutual NDA before the call

    We sign a mutual NDA before the initial call so you can share device details, architecture, and FDA correspondence freely.

    Fixed-fee quote within 24 hours of the call

    The quote identifies deliverables, assumptions, and dates. Quote turnaround is separate from the time needed to deliver the work.

    Senior US engineers, fixed fee

    Senior-led cybersecurity work within the agreed scope. Your team reviews the evidence and owns risk, release, and submission decisions.

    Common questions

    How fast can you respond to an FDA cybersecurity hold?

    Initial triage and quote turnaround are separate from delivery. After reviewing the letter, evidence, access, and remediation needs, we agree dates with your team. No universal completion window applies.

    What if my hold letter references older 2023-era guidance?

    The FDA's Feb 3, 2026 final premarket cybersecurity guidance is now the operative standard reviewers apply. We respond against the current guidance while mapping any language the hold letter cites back to the equivalent Feb 2026 sections, so nothing gets lost in translation.

    Will responding to a hold restart my 180-day review clock?

    The review clock pauses while you're on hold and resumes when the FDA accepts the response. We format the package to minimize back-and-forth so the clock restarts cleanly.

    Do you sign an NDA before reading my hold letter?

    Yes. Mutual NDA before the call, share the hold letter, submission excerpts, and any reviewer correspondence freely.

    What if the FDA comes back with follow-up questions?

    Fixed fee includes follow-up exchanges. We stay on the file until the cybersecurity hold is lifted.

    Are your engineers US-based?

    Yes. Senior US-based medical device cybersecurity specialist owns every FDA-facing deliverable. No offshoring.

    Christian Espinosa, Founder & CEO of Blue Goat Cyber

    Who you're talking to

    Christian Espinosa, Founder & CEO

    MBA, CISSP · U.S. Air Force Academy graduate · 30+ years in cybersecurity

    Christian leads the senior medical device cybersecurity team behind 275+ FDA submissions supported, zero cybersecurity rejections. Author of three books including Medical Device Cybersecurity: An In-Depth Guide.

    LinkedInFull bio

    Discuss your cybersecurity hold response

    30-minute call with a senior medical device cybersecurity expert. Fixed-fee quote within 24 hours of the scoping call. Delivery and review dates are agreed separately.

    Pick a time that worksCall (844) 939-4628
    Replies in 1 business day/Mutual NDA first/US-based senior engineer/No sales pitch
    See the full deficiency response service →

    Blue Goat Cyber

    Scottsdale, Arizona, USA · (844) 939-4628

    • Privacy Policy
    • Terms
    • Contact
    • Vulnerability Disclosure

    © 2026 Blue Goat Cyber. All rights reserved.

    CallBook free call